GB-0895 is being evaluated in two Phase 3 severe asthma studies for dosing twice a year
A single dose of GB-0895 produced sustained pharmacological activity for at least six months in COPD
Zealand Pharma collaboration provides
Anthropic collaboration builds on AI agent–guided CAR T research yielding smaller signaling domains with improved function in preclinical studies
Oncology clinical programs advance with second-cohort enrollment for GB-4362 in advanced urothelial cancer and first-patient dosing of GB-5267 in platinum-resistant ovarian cancer
Cash, cash equivalents, and marketable securities of
“Our third quarter results reflect both strong execution across all of our clinical programs and our continued efforts to push the frontiers of programmable biology and therapeutic intelligence,” said
Recent Progress
GB-0895 in severe asthma and COPD
GB-0895, Generate’s most advanced internal drug candidate, is an investigational anti-TSLP monoclonal antibody engineered with AI for dosing twice a year. The two global Phase 3 SOLAIRIA studies are ongoing in adults and adolescents with severe uncontrolled asthma, and recent Phase 1b results in COPD patients highlight an opportunity to expand into a large and underserved patient population.
Generate presented three posters on GB-0895 at the
- Phase 1 asthma findings. Complete Phase 1 findings showed that a single dose of GB-0895 sustained inflammatory biomarker reductions for at least six months in participants with mild-to-moderate asthma. At 300 mg, GB-0895 achieved maximal biomarker suppression and had a half-life of approximately 98 days, supporting the dosing interval being evaluated in Phase 3.
- Phase 1b COPD findings. A single dose of GB-0895 sustained inflammatory biomarker reductions for at least six months in participants with COPD. Comparable suppression was demonstrated for 300 mg and 600 mg, extending the evidence supporting six-month pharmacological activity to a second respiratory indication.
- SOLAIRIA Phase 3 study design. The study-design poster detailed the ongoing SOLAIRIA-1 and SOLAIRIA-2 trials in adults and adolescents with severe uncontrolled asthma. The replicate trials evaluate 300 mg administered every 26 weeks, with annualized asthma exacerbation rate over 52 weeks as the primary endpoint.
Zealand Pharma collaboration in obesity and metabolic diseases
On
The agreement covers two initial programs to develop multispecific protein therapeutics for obesity and other metabolic diseases, with an option to add a third for additional financial consideration. Generate will lead research through lead-candidate selection. Zealand will assume responsibility for subsequent preclinical and clinical development, regulatory submissions, and worldwide commercialization.
Anthropic collaboration and AI-driven CAR T-cell research
On
In early preclinical research, a team of six Generate scientists combined AI agents with the company’s computational and experimental capabilities over approximately six months to engineer a CAR signaling domain approximately 70% shorter than the second-generation design used for comparison. In laboratory tests, CAR T cells incorporating the compact domain showed improved tumor-cell killing compared with the comparison design.
The research also supported expression of four different CARs from a shared mRNA dose, suggesting potential applications in designs targeting multiple tumor antigens. The collaboration focuses on selecting and validating antigen combinations for early-stage solid tumors.
Oncology pipeline advances
GB-4362 aims to address treatment-limiting toxicities associated with antibody-drug conjugates, while GB-5267 is designed to address the difficulty of sustaining CAR T-cell activity in solid tumors.
- GB-4362 advanced to the second of potentially three dose-escalation cohorts. Enrollment has begun in the second cohort of the Phase 1 study evaluating GB-4362 with enfortumab vedotin and pembrolizumab in advanced urothelial cancer.
- On
Oct. 23 , Generate presented a trial-in-progress poster describing the Phase 1 clinical study design of GB-4362 at the 2026European Society for Medical Oncology Congress inMadrid . - On
Oct. 1 , Generate andRoswell Park Comprehensive Cancer Center announced that the first patient had been dosed in the Phase 1 study of the investigational autologous IL-18-armored CAR T-cell therapy in platinum-resistant ovarian cancer. GB-5267 targets MUC16, an antigen overexpressed in more than 80% of ovarian tumors, and was engineered with AI to optimize tumor-cell killing, T-cell expansion, and persistence. The trial begins the clinical evaluation of that function-first design without requiring chemotherapy-based lymphodepletion. - On
Oct. 18 ,Roswell Park delivered an oral presentation at the 16th Biennial Rivkin Ovarian Cancer Research Symposium inPhiladelphia detailing the scientific rationale and study design. The presentation highlighted IL-18 armoring intended to support CAR T-cell activity and a Phase 1 study evaluating GB-5267 without chemotherapy-based lymphodepletion
“We continue to advance GB-0895 through the Phase 3 SOLAIRIA studies in severe asthma and make progress across our clinical pipeline. Following the quarter-end, we also entered into a new collaboration agreement with Zealand Pharma,” said
Financial Results
Cash, cash equivalents, and marketable securities were
Revenue for the quarter ended
Research and development expenses were
General and administrative expenses were
Net loss was
About Generate Biomedicines
Generate (Nasdaq: GENB) is a clinical-stage generative biology company founded at the intersection of machine learning, biological engineering, and medicine, advancing a new era of programmable biology to engineer better drug candidates for patients, faster. The Generate Platform integrates computational design with large-scale biological experimentation, enabling the creation of novel, optimized therapeutics that address historically undruggable and hard-to-drug targets, as well as known targets in new and more effective ways. The platform has enabled the generation of a broad pipeline across multiple therapeutic areas and protein-based modalities, addressing health challenges out of reach of traditional approaches. Founded in 2018, Generate is leading a fundamental shift from drug discovery to drug generation. Learn more at www.generatebiomedicines.com or follow us on X, LinkedIn, and YouTube.
Digital Media Disclosure
From time to time Generate has used, or expects in the future to use, its investor website (investors.generatebiomedicines.com), the Generate LinkedIn account (linkedin.com/company/generate-biomedicines), and the Generate X account (@generate_biomed) as means of disclosing information to the public in a broad, nonexclusionary manner, including for purposes of the SEC’s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor the investor website and these social media channels in addition to news releases, SEC filings, public conference calls, and webcasts, as the information posted on them could be material to investors.
Cautionary Note Regarding Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the advancement of Generate’s drug candidates; the initiation, design, conduct, timing, progress, and results of preclinical studies and clinical trials, including SOLAIRIA-1 and SOLAIRIA-2 and the Phase 1 studies of GB-5267 and GB-4362; the potential benefits of GB-0895 and dosing twice a year; the likelihood and timing of a decision to proceed with development of GB-0895 in COPD; the scope and potential benefits of the collaboration with Zealand, including the design and development of multispecific protein therapeutics, the potential addition of a third program, and the potential milestone payments and royalties; the scope and potential benefits of the research collaboration with Anthropic, including the application of agentic methods to target selection and validation and further development of redesigned CAR signaling domains; Generate's expected cash runway; and the expected enhancements, benefits, and potential of The Generate Platform.
In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “would,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential,” or “continue,” or the negative of these terms or other similar expressions.
These forward-looking statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including, but not limited to, risks and uncertainties related to Generate’s ability to successfully develop and obtain regulatory approval for its drug candidates; the initiation, design, progress, timing, and results of preclinical studies and clinical trials; Generate’s ability to obtain, maintain, and enforce intellectual property protection; Generate’s dependence on third parties for the manufacturing and development of its drug candidates; Generate's ability to realize the intended benefits of collaborations with third parties; the impact of competitive products and technologies; Generate’s ability to replicate results from earlier preclinical studies or clinical trials in current or future clinical trials; Generate’s ability to demonstrate that its drug candidates are safe and effective for their proposed indications; Generate’s ability to obtain additional capital to fund its operations; and general economic, industry, and market conditions.
Additional information on these and other risks and uncertainties that could affect Generate’s business, financial condition, and results of operations is included in Generate’s filings with the Securities and Exchange Commission, including its Quarterly Reports. The forward-looking statements in this news release are made as of the date hereof, and Generate undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this news release, except as required by applicable law.
Generate Media Contact
Megan McLaughlin
pr@generatebiomedicines.com
CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) (unaudited) | ||||||||
| As of | As of | |||||||
| 2026 | 2025 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 140,350 | $ | 121,650 | ||||
| Marketable securities | 263,862 | 99,848 | ||||||
| Restricted cash and cash equivalents (VIE) | — | 339 | ||||||
| Prepaid expenses and other current assets | 10,429 | 12,528 | ||||||
| Total current assets | 414,641 | 234,365 | ||||||
| Property and equipment, net | 38,653 | 29,151 | ||||||
| Operating lease right-of-use assets | 53,255 | 59,860 | ||||||
| Other assets | 9,341 | 6,806 | ||||||
| Total assets | $ | 515,890 | $ | 330,182 | ||||
| Liabilities, convertible preferred stock, non-controlling interest and stockholders’ deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable(1) | $ | 7,892 | $ | 3,837 | ||||
| Accrued expenses and other current liabilities | 43,554 | 42,164 | ||||||
| Deferred revenue - current | 7,947 | 21,194 | ||||||
| Current portion of finance lease liabilities | 12,499 | 4,311 | ||||||
| Operating lease liabilities - current | 10,830 | 10,697 | ||||||
| Total current liabilities | 82,722 | 82,203 | ||||||
| Non-current liabilities: | ||||||||
| Warrant to purchase convertible preferred stock | — | 1,205 | ||||||
| Non-current portion of finance lease liabilities | 5,891 | 2,908 | ||||||
| Deferred revenue - non-current | — | 4,511 | ||||||
| Operating lease liabilities - non-current | 46,121 | 50,610 | ||||||
| Other long term liabilities | — | 116 | ||||||
| Total liabilities | 134,734 | 141,553 | ||||||
| Commitments and contingencies (Note 13) | ||||||||
| Convertible preferred stock | — | 811,826 | ||||||
| Non-controlling interest | — | (7,232 | ) | |||||
| Stockholders’ equity (deficit): | ||||||||
| Common stock, par value | 129 | 33 | ||||||
| Additional paid-in capital | 1,273,942 | 60,189 | ||||||
| Accumulated other comprehensive (loss) income | (264 | ) | 106 | |||||
| Accumulated deficit | (892,651 | ) | (676,293 | ) | ||||
| Total stockholders’ equity (deficit) | 381,156 | (615,965 | ) | |||||
| Total liabilities, convertible preferred stock, non-controlling interests and stockholders’ equity (deficit) | $ | 515,890 | $ | 330,182 | ||||
| (1) | Includes related party amounts of |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (in thousands, except share and per share data) (unaudited) | ||||||||||||||||
| Three Months Ended | Nine Months Ended | |||||||||||||||
| 2026 | 2025 | 2026 | 2025 | |||||||||||||
| Collaboration revenue | $ | 4,220 | $ | 9,634 | $ | 17,758 | $ | 28,582 | ||||||||
| Operating expenses: | ||||||||||||||||
| Research and development(1) | 82,254 | 62,151 | 204,396 | 168,711 | ||||||||||||
| General and administrative(2) | 13,473 | 10,295 | 40,595 | 30,987 | ||||||||||||
| Total operating expenses | 95,727 | 72,446 | 244,991 | 199,698 | ||||||||||||
| Loss from operations | (91,507 | ) | (62,812 | ) | (227,233 | ) | (171,116 | ) | ||||||||
| Other income (expense), net | ||||||||||||||||
| Change in fair value of convertible preferred stock warrant liability | — | — | (363 | ) | — | |||||||||||
| Interest expense | (192 | ) | (253 | ) | (529 | ) | (928 | ) | ||||||||
| Interest income | 4,149 | 3,105 | 11,691 | 11,175 | ||||||||||||
| Foreign currency exchange loss | (58 | ) | (39 | ) | (62 | ) | (86 | ) | ||||||||
| Total other income (expense), net | 3,899 | 2,813 | 10,737 | 10,161 | ||||||||||||
| Loss before provision for income taxes | (87,608 | ) | (59,999 | ) | (216,496 | ) | (160,955 | ) | ||||||||
| Provision for income taxes | (49 | ) | (34 | ) | (130 | ) | (134 | ) | ||||||||
| Net loss | (87,657 | ) | (60,033 | ) | (216,626 | ) | (161,089 | ) | ||||||||
| Net loss attributable to non-controlling interests | — | (6,418 | ) | (268 | ) | (13,360 | ) | |||||||||
| Net loss attributable to | (87,657 | ) | (53,615 | ) | (216,358 | ) | (147,729 | ) | ||||||||
| Convertible preferred stock accrued dividends | — | (11,592 | ) | (7,749 | ) | (34,777 | ) | |||||||||
| Net loss attributable to | $ | (87,657 | ) | $ | (65,207 | ) | $ | (224,107 | ) | $ | (182,506 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.68 | ) | $ | (1.97 | ) | $ | (2.09 | ) | $ | (5.54 | ) | ||||
| Weighted average common shares outstanding, basic and diluted | 128,514,700 | 33,038,657 | 107,441,915 | 32,943,260 | ||||||||||||
| Other comprehensive loss: | ||||||||||||||||
| Net loss | (87,657 | ) | (60,033 | ) | (216,626 | ) | (161,089 | ) | ||||||||
| Unrealized (loss) gain on marketable securities | (135 | ) | 132 | (370 | ) | 4 | ||||||||||
| Comprehensive loss | $ | (87,792 | ) | $ | (59,901 | ) | $ | (216,996 | ) | $ | (161,085 | ) | ||||
| Comprehensive loss attributable to non-controlling interest | — | (6,418 | ) | (268 | ) | (13,360 | ) | |||||||||
| Comprehensive loss attributable to | $ | (87,792 | ) | $ | (53,483 | ) | $ | (216,728 | ) | $ | (147,725 | ) | ||||
| (1) | Includes related party amounts of |
| (2) | Includes related party amounts of |
Source: